Malcherczyk Dominik, Heyse Thomas J, El-Zayat Bilal F, Kunzke Vanessa, Moll Roland, Fuchs-Winkelmann Susanne, Paletta Jürgen R J
Center for Orthopedics and Trauma Surgery, University Hospital Marburg, Baldingerstrasse, 35043, Marburg, Germany.
Department of Pathology, University Hospital Marburg, Marburg, Germany.
BMC Musculoskelet Disord. 2018 Jan 9;19(1):9. doi: 10.1186/s12891-017-1920-7.
Chondrosarcoma is the second most common primary malignant bone tumor. Because of their heterogeneity, with differences in invasive and metastatic behavior, it is important to identify biological markers that will allow for a more accurate estimation of prognosis in patients with these tumors. Matrix metalloproteinases (MMP) play a crucial role in tumor progression, invasion and metastasis. The mechanism of tumor progression dependent of MMPs is complex and influences malignant transformation, angiogenesis and tumor growth at the primary and metastatic sites. The purpose of this study was to investigate immunohistochemicaly the influence of MMP-1, MMP-3, MMP-9 and MMP-13 expression on prognostic parameter in chondrosarcoma.
We investigated tissue samples of 28 patients with chondrosarcoma. Immunohistochemical staining to evaluate the expression of MMP-1, MMP-3, MMP-9 and MMP-13 was performed. Subsequently, the expression level was correlated with metastatic potential, histological grading and overall survival in patients with this neoplasm.
In consideration of semi quantitative scoring 64% of chondrosarcoma were scored as positive for MMP-1, 46% for MMP-3, 61% for MMP-9. The specimens had shown no expression of MMP-13. High expression of MMP-9 was associated with better histological differentiation, decreased metastatic potential and favourable overall survival. No correlation was found for expression of MMP-1, MMP-3 or MMP-13.
MMP-1, MMP-3 and MMP-9 are expressed in chondrosarcoma. Our findings suggest that the expression of MMP-9 is associated with clinical outcome parameters in chondrosarcoma.
软骨肉瘤是第二常见的原发性恶性骨肿瘤。由于其异质性，侵袭和转移行为存在差异，因此识别能够更准确评估这些肿瘤患者预后的生物标志物非常重要。基质金属蛋白酶（MMP）在肿瘤进展、侵袭和转移中起关键作用。依赖MMP的肿瘤进展机制复杂，影响原发和转移部位的恶性转化、血管生成和肿瘤生长。本研究的目的是通过免疫组织化学方法研究MMP-1、MMP-3、MMP-9和MMP-13表达对软骨肉瘤预后参数的影响。
我们研究了28例软骨肉瘤患者的组织样本。进行免疫组织化学染色以评估MMP-1、MMP-3、MMP-9和MMP-13的表达。随后，将表达水平与该肿瘤患者的转移潜能、组织学分级和总生存期相关联。
考虑半定量评分，64%的软骨肉瘤MMP-1评分为阳性，46%的MMP-3为阳性，61%的MMP-9为阳性。标本未显示MMP-13的表达。MMP-9的高表达与更好的组织学分化、降低的转移潜能和良好的总生存期相关。未发现MMP-1、MMP-3或MMP-13的表达存在相关性。
MMP-1、MMP-3和MMP-9在软骨肉瘤中表达。我们的研究结果表明，MMP-9的表达与软骨肉瘤的临床结局参数相关。
